



Evaluation of a post-discharge pharmacist opioid review following total knee arthroplasty: a pre- and post-intervention cohort study

Tim Tran^{1,2} · James Ford¹ · Andrew Hardidge³ · Shari Antoine⁴ · Beth Veevers⁴ · Simone Taylor¹ · Rohan A. Elliott^{1,2}

Received: 10 March 2022 / Accepted: 25 June 2022
© The Author(s), under exclusive licence to Springer Nature Switzerland AG 2022

Abstract

Background More than 70% of patients continue to use opioid medications 3-weeks following total knee arthroplasty. Post-discharge pharmacist reviews improve medication management, however its effect on opioid usage is not known.

Aim This study aimed to evaluate the impact of post-discharge pharmacist review on opioid use following a total knee arthroplasty.

Method A pilot, cohort pre- and post-intervention study was undertaken on patients who had undergone a total knee arthroplasty and were supplied an opioid upon discharge from hospital. During the intervention, patients were contacted via telephone by a pharmacist approximately five days post-discharge to review analgesic usage, provide education and advice and communicate an opioid management plan to their general practitioner. The primary endpoint was the percentage of patients taking opioids 3-weeks post-discharge. Secondary endpoints included: percentage of patients obtaining an opioid refill; patient satisfaction with opioid supply and the pharmacist review.

Results Pre- and post-intervention, 63 and 44 patients were included, respectively. The percentage of patients taking opioids 3-weeks post-discharge declined from 74.6 to 29.6% ($p < 0.001$) and the percentage requiring an opioid refill from their general practitioner declined from 71.4 to 36.4% ($p < 0.001$). More patients were satisfied with opioid supply during the intervention period (79.5% cf. 47.6%, $p = 0.001$). Twenty-eight (63.6%) patients could recall the post-discharge pharmacist review, and all were either satisfied or extremely satisfied with the review.

Conclusion Pharmacist-delivered post-discharge analgesia review reduced the percentage of patients taking opioids 3-weeks post-discharge following a total knee arthroplasty. This intervention has the potential to provide a smoother transition of care for patients supplied with opioids at the time of hospital discharge.

Keywords Opioids · Orthopedic surgery · Pharmacist · Transitions of care

Impact statements

✉ Tim Tran
tim.tran@austin.org.au

- 1 Pharmacy Department, Austin Health, Heidelberg, VIC, Australia
- 2 Centre for Medicine Use and Safety, Faculty of Pharmacy and Pharmaceutical Sciences, Monash University, Parkville, VIC, Australia
- 3 Orthopaedic Surgery, Austin Health, Heidelberg, VIC, Australia
- 4 Health Independence Program, Austin Health, Heidelberg, VIC, Australia

- Post-discharge pharmacist analgesia review may reduce opioid usage 3-weeks after discharge following total knee arthroplasty;
- Fewer patients who received a post-discharge pharmacist review required ongoing opioid supply from their general practitioner;
- Post-discharge pharmacist analgesia review may improve transitions of care when patients are discharged from hospital to the community.

Introduction

The opioid crisis has seen a rise in the number of opioid prescriptions, with a subsequent increase in unintentional drug-related deaths [1–3]. As a result, interventions have focused on reducing opioid availability in the community. Interventions have included regulatory and legislative changes, the introduction of institutional guidelines, pharmacist review of discharge prescriptions and use of educational strategies directed towards patients and prescribers [4–8]. A uniform reduction in the supply of opioids post-operatively may have adverse consequences on subsets of patients who may require them for an extended period, such as those undergoing major orthopedic surgery [9–11].

Studies in the United States (US) have shown that patients undergoing joint arthroplasty are often prescribed larger quantities of opioids compared to other surgical procedures [12, 13]. A study in our health service demonstrated that over 70% of patients who underwent a total knee arthroplasty (TKA) and were discharged with an opioid, were still taking them 3-weeks after hospital discharge [11]. Furthermore, over 70% of patients required a refill prescription from their general practitioner (GP), in addition to the opioids provided by the hospital at the time of discharge [11]. A follow-up study evaluating discharge summaries sent to GPs when surgical patients were discharged from hospital with an opioid found errors in opioid information (e.g. wrong dose, duration, quantity) in almost 25% of discharge summaries [14]. Only 13% of summaries contained an opioid weaning schedule, a cease date and a plan for review (referred to as an opioid management plan). Of the GPs surveyed, 60% were dissatisfied or very dissatisfied with the opioid-related information provided [14]. These results highlight the urgent need to improve transitions of care when surgical patients are supplied with opioids upon hospital discharge.

Post-discharge pharmacist reviews may assist with transitions of care. An example of this is hospital outreach medication review (HOMR) provided by a pharmacist. HOMRs involve a pharmacist conducting a review of the patient's medication and medication management. Actual or potential medication related problems are communicated to the patient's GP. Patients targeted are often older, have multiple pre-existing co-morbidities, are taking multiple medications and may have disabilities that affect their ability to take their medications correctly (e.g. dexterity problems, impaired cognition, vision or hearing) [15]. These services have been demonstrated to improve medication knowledge, medication adherence and reduced hospital readmissions in some high-risk patient groups [16, 17]. To date, no studies have evaluated the impact of post-discharge pharmacist reviews on opioid use.

Aim

This study aimed to evaluate the impact of post-discharge pharmacist review on opioid use following TKA.

Ethics approval

This study was approved by the Human Research Ethics Committee at Austin Health as a quality improvement study (reference 38,606) on 17/2/2020.

Method

A pre- and post-intervention study was undertaken at a 790-bed public health service in Melbourne, Australia over two time periods (December 2017 to July 2018 and January 2020 to July 2020). The intervention was introduced during a one-month run-in period (December 2019) prior to commencement of the post-intervention period. The methodology for the pre-intervention evaluation of usual care has been detailed elsewhere [11]. The methodology below focuses on the post-intervention period, but briefly outlines key details of the pre-intervention study.

Study recruitment

All patients who had undergone a TKA and were supplied with an opioid upon discharge, were included in this study. Consecutive patients were invited to participate by the surgical unit clinical pharmacist and were asked to provide verbal consent. Patients' caregivers were also asked to provide consent if they were responsible for the management of the patient's medications, as they would need to be interviewed. Patients were excluded if they required an interpreter, were readmitted to hospital within 3-weeks of hospital discharge or were unable to be contacted by telephone post-discharge after three attempts.

Hospital discharge process: usual care

The hospital discharge process was identical in both the pre- and post-intervention periods. When patients were confirmed for discharge, a hospital prescription was electronically generated by the hospital medical officer (HMO) using Cerner Millennium. The prescription was given to the clinical pharmacist who undertook medication review and reconciliation and discussed the prescription with the patient, to review their pain control and opioid requirements. Any prescription changes proposed by the pharmacist were discussed with the HMO and the prescription was modified. The medications were then dispensed by the hospital

pharmacy and provided to the patient along with medication education from the pharmacist prior to discharge.

Post-discharge pharmacist review: intervention

The post-discharge pharmacist review was undertaken by one of three HOMR pharmacists employed by the health service. The HOMR pharmacists each had between 15 and 30 years of experience as a pharmacist. Intervention patients were contacted via telephone by the HOMR pharmacist approximately three to five days after hospital discharge. The pharmacist ascertained the current analgesics and how they were being used by the patient, and explored the use of any non-pharmacological management strategies. They provided education and advice to the patient about optimizing their analgesics (e.g. ensuring non-opioids such as paracetamol were used at maximal doses), incorporation of non-pharmacological strategies, expectations about the duration of opioid use and when (if required) to review their analgesics with their GP. In addition, pharmacists could refer patients to the hospital's Peri-Operative Pain Management, Education and De-escalation (POPPMED) clinic if they felt that specialist review was required. The POPPMED clinic was serviced by an anesthetist and two specialist pain consultant nurses. Patients could also be referred to the clinic during their inpatient stay by HMOs and pharmacists if they were deemed to be at high risk for developing chronic opioid use. A written report outlining the patient's analgesic usage and recommendations made by the pharmacist was provided to the patient's GP (via facsimile) and scanned into the hospital medical record. The post-discharge pharmacist review was not provided to any patients during the pre-intervention period.

Patient survey

During the pre- and post-intervention periods, patients or their carers participated in a telephone interview 3-weeks after hospital discharge. Interviews were conducted by a pharmacist not involved in the patient's care. For each interview, there were three attempts made to contact the patient or caregiver over a one week period. The same questionnaire was used during the pre- and post-intervention periods, to allow comparison between the patient groups (Table 1) [11]. In addition, post-intervention patients were asked whether they recalled receiving a telephone review from a pharmacist after hospital discharge and their level of satisfaction with the service on a scale of 1 to 5 (with 1 being extremely dissatisfied and 5 being extremely satisfied).

Opioid naïve patients who commenced on opioids in hospital and were still taking them at the 3-week post-discharge interview, were telephoned again at 3-months after discharge to determine whether they were still taking opioids (and had therefore transitioned to prolonged use).

Data collection

Patient demographics, length of hospital stay and number of comorbidities were obtained from the hospital's electronic medical record. The number of regular medications and types of analgesics used pre-admission were obtained from the hospital's Medication History on Admission Form completed by a clinical pharmacist. Patients were deemed to be opioid naïve if they were not taking any opioids immediately prior to their hospital admission (regular or *prn* ["as required"]). The number of *prn* doses of breakthrough opioids used 24 h prior to discharge was obtained from the medication administration record. Analgesics and quantities supplied on discharge were obtained from the hospital pharmacy dispensing system. An analgesic was defined as any medication used to treat or prevent pain [18]. Between the pre- and post-intervention periods, ascorbic acid (to prevent

Table 1 Survey questions

(Before interview, interviewer to obtain a list of pain medicines dispensed to the patient on hospital discharge)
 On discharge from hospital, you were prescribed pain medicines. Can you tell me if you are still taking these medicines and how you are using them? [interviewer to prompt if patient can't recall the medicines]

(The following questions are to be asked for each pain medicine that the patient was dispensed on discharge)
 Are you still taking this medicine?
 Did you think you were provided with enough of this medicine when you were discharged?
 (if no longer taking) Did you discard them?
 (if no longer taking) Why did you stop taking the medicine?
 (if no longer taking) How many tablets/capsules do you have left?
 (if still taking) How are you taking the medicine (include if regular or "prn")?
 (if still taking) Who did you obtain a prescription from to obtain further supply?
 Are you currently taking any additional pain medicines including medicines you have obtained without a prescription that we have not already mentioned? (if yes, obtain name, strength, frequency, and who the prescription was obtained from)
 Do you have any additional comments?

complex regional pain syndrome) was removed from the orthopedic unit's pain management protocol and therefore data from the pre-intervention period was amended to exclude ascorbic acid use from these results. Analgesics with multiple forms were considered individually (e.g. short and long acting agents), whereas multiple strengths of the same medication in the same dose-form were considered as one. Opioids were converted to an analgesic equivalent dose of oxycodone and 5 mg oxycodone was deemed equivalent to one opioid pill [18].

Reports prepared by the pharmacist as part of the post-discharge review were retrospectively reviewed by a study investigator (TT). A descriptive analysis was undertaken of the types of recommendations and advice provided by the pharmacist.

Endpoints

The primary endpoint was the percentage of patients who were still taking opioids 3-weeks after hospital discharge. Secondary endpoints were:

- Number of hospital-supplied opioid pills remaining 3-weeks after discharge;
- Percentage of patients needing to obtain an opioid refill prescription from their GP;
- Percentage of patients who felt that they had adequate supplies of opioids upon hospital discharge;
- Percentage of opioid naïve patients who became chronic opioid users (continued usage beyond 3-months post-discharge);
- Percentage of patients who could recall having their medications reviewed after discharge by the pharmacist;
- Patient satisfaction with the post-discharge pharmacist review;
- Recommendations and advice provided by the pharmacist.

Sample size calculation

During the pre-intervention period, out of 63 patients who underwent a TKA and were supplied with an opioid on discharge, 74.6% were still taking an opioid at 3 weeks post discharge. If a clinically significant reduction in the percentage of TKA patients taking an opioid at 3 weeks is a one-third reduction (to 49.2%), then at least 62 patients were needed in each group (80% power, 2-sided alpha 0.05). We therefore aimed to recruit the same number of patients ($n = 63$) to the post-intervention group. This study was terminated early after only 44 patients were recruited, because elective surgery at the study hospitals was cancelled for a prolonged period due to the COVID-19 pandemic. A post-hoc power calculation whereby 29.5% of post-intervention patients

were still taking an opioid at 3 weeks revealed that the study had 99.7% power (alpha 0.05) to detect a difference between the groups if one existed.

Statistical analysis

Statistical analysis was undertaken using SPSS version 26 (IBM Corporation, Armonk, NY). Median and interquartile range (IQR) were used to describe non-normally distributed data, whereas the mean and standard deviation (SD) were used to describe normally distributed data. Chi-square test was used to compare differences in percentages. Student's *t* test was used to compare means, while Mann–Whitney *U* test was used to compare distributions of non-normally distributed data. A *p* value of less than 0.05 was considered to be statistically significant for all comparisons.

Results

In the pre-intervention period, 110 patients underwent a TKA and 47 were excluded (24 were not able to be consented, 10 declined to participate, 4 required an interpreter and 9 were lost to follow-up), such that 63 patients were able to be evaluated in this study. In the post-intervention period, 52 patients underwent a TKA. Eight patients were excluded from the study (5 were not able to be contacted, 2 required an interpreter and 1 was readmitted) leaving a total of 44 patients included in the analysis. Due to the COVID-19 pandemic, elective surgery was cancelled which resulted in the study being terminated after 6 months. Baseline demographic characteristics for both periods are shown in Table 2. Patients recruited during the intervention had more medical conditions ($p = 0.031$) and were discharged with fewer opioid pills ($p = 0.001$). During the pre-intervention period, patients were discharged with more analgesic products ($p < 0.001$), with greater use of pregabalin ($p < 0.001$).

In the post-intervention period, two patients were seen in the POPPMED clinic for ongoing management of their analgesics. One of these patients was no longer taking opioids at 3-weeks after discharge, whereas the other was still taking them. These patients were referred to the clinic during the inpatient admission and not following the post-discharge pharmacist review.

Primary endpoint

In the pre- and post-intervention periods respectively, 47/63 (74.6%) and 13/44 (29.5%) patients were still taking opioids 3-weeks after hospital discharge (Table 3).

Table 2 Demographic characteristics

	Pre-intervention (n=63)	Post-intervention (n=44)
Age, years, median (IQR)	68 (62–74)	72.5 (64–79)
Male gender, n (%)	21 (33.3)	19 (43.2)
Length of stay, days, median (IQR)	4 (3–5)	4.5 (3–7)
Number of medical conditions, median (IQR)	4 (3–6)	5 (4–7)
Number of regular admission medications, median (IQR)	4 (3–8)	6 (4–9)
Opioid use pre-admission, n (%)	17 (27.0)	11 (25.0)
Type of analgesics prescribed on discharge, n (%)		
Paracetamol	61 (97.0)	43 (97.7)
Oxycodone long-acting	42 (66.7)	26 (59.1)
Oxycodone short-acting	58 (92.1)	35 (79.5)
Pregabalin	34 (54.0)	2 (4.5)
Tapentadol long-acting	12 (19.0)	4 (9.1)
Tapentadol short-acting	4 (10.0)	6 (13.6)
NSAID	8 (12.7)	3 (6.8)
Tramadol long-acting	0 (0)	1 (0)
Tramadol short-acting	5 (7.9)	5 (11.4)
Buprenorphine patch	1 (2.0)	0 (0)
Number of <i>prn</i> doses of breakthrough opioids used in the 24 h before discharge, median (IQR)	3 (2–4)	4 (2–5)
Number of analgesics prescribed on discharge, mean (SD)	3.6 (0.91)	2.8 (0.78)
Number of opioid pills supplied per patient, median (IQR)	35 (25–40)	20 (13.8–36.8)

SD standard deviation, *IQR* interquartile range

Table 3 Opioid use 3-weeks after hospital discharge

	Pre-intervention (n=63)	Post-intervention (n=44)	<i>p</i> value
Patients still taking opioids 3-weeks after hospital discharge, n (%)	47 (74.6)	13 (29.5)	<0.001
Total number of opioid pills remaining 3-weeks after hospital discharge, median (IQR)	0 (0–2)	0 (0–7)	0.527
Patients reporting an adequate supply of opioids, n (%)	30 (47.6)	35 (79.5)	<i>p</i> =0.001
Patients needing to obtain further opioid prescriptions from their general practitioner, n (%)	45 (71.4)	16 (36.4)	<i>p</i> <0.001

Secondary endpoints

The median number of hospital-supplied opioid pills remaining 3-weeks after discharge was zero in both pre- and post-intervention periods (Table 3). The percentage of patients who saw their GP to obtain further opioid prescriptions declined from 71.4% in the pre-intervention group to 36.4% post-intervention. There were 33 patients who were opioid naïve prior to their TKA in the post-intervention period and none of these patients developed chronic opioid use. This is in contrast to 5.3% of the 46 opioid naïve patients in the pre-intervention period who developed chronic opioid use. During the post-intervention period, 35/44 (79.5%) patients reported that they had an adequate supply of their opioids,

compared to 30/63 (47.6%) during the pre-intervention period.

At the 3-week interview, there were 28/44 (63.6%) post-intervention patients who recalled receiving a post-discharge telephone review from the pharmacist. Of these patients, 26/28 were extremely satisfied and the remaining 2/28 were satisfied with the service.

The pharmacists' written reports for 40 patients were reviewed with all providing an action and recommendation (4 reports were not available in the medical records). The pharmacist conducted the review with the patient a median of 3 days (IQR 2–4) following hospital discharge. There were 4 patients who required a follow-up review by the pharmacist after their initial review. Actions and recommendations provided by the pharmacist are summarized in Table 4.

Table 4 Actions and recommendations made by the pharmacist during the post-discharge review

Actions and recommendations	Number of patients, n (%) (n = 40)
Provided education about the use of non-pharmacological pain management	8 (20.0)
Provision of education about the expected duration of opioid use	22 (55.0)
Recommendations related to opioid(s)	
Continue current opioid plan	30 (75.0)
Dose escalation	2 (5.0)
Dose reduction	12 (30.0)
Cessation	11 (27.5)
Optimization of non-opioid analgesics	9 (22.5)
Education and recommendations related to management of opioid-related adverse effects	7 (17.5)

Discussion

This study explored a novel use of the pharmacist in providing post-discharge follow-up care and education to patients about pain management following a TKA, and providing information and recommendations to patients' GPs in relation to their pain management plan. Patients who received a review by the pharmacist within a week after discharge were less likely to be taking opioids 3-weeks following hospital discharge.

The pharmacist had the opportunity to review how patients were managing their analgesics and was able to provide recommendations to them on pharmacological and non-pharmacological strategies to improve overall pain management. Furthermore, the pharmacist was able to assess the patient's understanding of the opioid management plan and provide education on the anticipated duration of opioid use, to minimize the risk of these medications inadvertently being prescribed for a prolonged period [19]. Numerous studies have demonstrated the benefits that patient education can have on reducing opioid use and improving pain and functional outcomes [6, 20, 21]. Studies have also demonstrated the benefits that pharmacists can have on de-escalating opioids during hospital admission, however, no studies have evaluated the impact that pharmacists can have following hospital discharge [22, 23]. Whilst our study did not evaluate pain or functional outcomes, more patients who received the post-discharge review were satisfied with the quantity of opioids supplied, despite being supplied smaller quantities compared with the pre-intervention group.

An important role of the pharmacist was to enhance communication of the patient's pain management plan to their GP and provide an assessment and recommendations related to opioid use in the week after discharge. Studies have shown that the hospital discharge summary provided to GPs is often inaccurate and lacks a detailed opioid management plan [14]. Without this information, GPs may inadvertently continue prescribing opioids, which can consequently

increase the risk of chronic opioid use [11, 24]. Whilst a comprehensive summary prepared by the pharmacist was provided to the GP, our study did not evaluate the effect that this had directly on GPs and therefore further studies are required to determine this. Our study did find that the percentage of patients who required a refill of their opioid prescriptions by their GP was significantly reduced in the post-intervention group.

Our study reported low utilization of the POPPMED clinic as part of this study, to manage patients at a higher risk of developing chronic opioid use. This clinic was established in response to feedback provided by GPs who found it difficult to manage some complex patients in the community [14]. Only two patients were reviewed in the POPPMED clinic so this was unlikely to have confounded our results. No patients were referred to the POPPMED clinic by a HOMR pharmacist. Future studies could develop defined referral criteria to target patients at risk of chronic use, that could aid the HOMR pharmacist in referring to this service.

There were several limitations to this study. There was an 18-month time lapse between the pre- and post-intervention periods. During this period in 2019, an organizational-wide prescribing guideline was implemented to assist in rationalizing opioid prescribing in surgical patients. The guideline provided clearer recommendations on the quantity of opioids to prescribe on discharge according to the prior 24-h usage of oxycodone (e.g. if < 15 mg used, then a maximum of five oxycodone immediate release tablets was recommended). This may have explained the significant difference in the number of opioid pills supplied to patients at hospital discharge during the post-intervention period. The impact this had on our results is difficult to predict; supplying fewer opioid pills may have reduced the risk of chronic use, however it may also have resulted in an undersupply of opioids for patients who had painful surgeries such as arthroplasty, which would have led to a need for additional prescribing (refills) by the GP. We found a reduction in the number of patients seeking refills from their GP despite a reduction in

the number of pills provided by the hospital. This suggests that the reduction in opioid use at 3-weeks post discharge may be attributable to the pharmacy review and its focus on clarifying the duration of opioid treatment and encouraging use of non-opioid analgesia and non-pharmacological strategies. Another practice change that was observed was the use of pregabalin. During the pre-intervention period, pregabalin was prescribed routinely to reduce post-operative pain, however, with emerging evidence suggesting little benefit, there was a reduction in the prescription of this medication during the post-intervention period [25]. Further studies are therefore required to validate these findings, ideally using a controlled trial design to better account for changes in prescribing practices over time. Our study was single-centered and only evaluated patients following TKA. This may affect the generalizability, as there are varying prescribing and dispensing practices across organizations, countries and even different surgical units. Further studies are required to fully evaluate the impact that this intervention could have in a range of settings as well as determining the resource and time requirements to undertake this additional role. Finally, the sample size of this study was small and was impacted by the COVID-19 pandemic which resulted in cancellations to elective surgery. Nonetheless, a post-hoc power calculation indicated power in excess of 90% and the primary endpoint achieved statistical significance. However, larger studies are required to explore the effect on some of the secondary endpoints, such as the impact on development of chronic opioid use.

Conclusion

This pilot study found that fewer patients who received a post-discharge pharmacist review of their opioids were taking them 3-weeks after discharge following a TKA, compared to patients who didn't receive a pharmacist review. Larger controlled studies are required to validate these findings.

Acknowledgements The authors thank Dr. Ilonka Meyer and Dr. Charlotte Heldreich for their assistance with this research.

Funding No specific funding was received.

Conflicts of interest The authors have no conflicts of interest to declare.

References

1. Adewumi AD, Maravilla JC, Alati R, et al. Pharmaceutical opioids utilisation by dose, formulation, and socioeconomic status in Queensland, Australia: a population study over 22 years. *Int J Clin Pharm*. 2021;43(2):328–39.
2. Pilgrim JL, Yafistham SP, Gaya S, et al. An update on oxycodone: lessons for death investigators in Australia. *Forensic Sci Med Pathol*. 2015;11(1):3–12.
3. Roxburgh A, Bruno R, Larance B, et al. Prescription of opioid analgesics and related harms in Australia. *Med J Aust*. 2011;195(5):280–4.
4. Australian Government Department of Health. Revised opioids PBS listings from 1 June 2020. <https://www.pbs.gov.au/info/news/2020/05/revise-opioids-pbs-listings-from-1-june-2020>. Accessed 14 Dec 2020.
5. Khorfan R, Shallcross ML, Yu B, et al. Preoperative patient education and patient preparedness are associated with less postoperative use of opioids. *Surgery*. 2020;167(5):852–8.
6. Parsa FD, Pavlosky KK, Harbison G, et al. Effect of preoperative patient education on opioid consumption and well-being in breast augmentation. *Plast Reconstr Surg*. 2020;145(2):316e–23e.
7. Stepan JG, Lovecchio FC, Premkumar A, et al. Development of an institutional opioid prescriber education program and opioid-prescribing guidelines: impact on prescribing practices. *J Bone Joint Surg Am*. 2019;101(1):5–13.
8. Tran T, Taylor SE, Hardidge A, et al. Impact of pharmacists assisting with prescribing and undertaking medication review on oxycodone prescribing and supply for patients discharged from surgical wards. *J Clin Pharm Ther*. 2017;42(5):567–72.
9. Chan EY, Blyth FM, Nairn L, et al. Acute postoperative pain following hospital discharge after total knee arthroplasty. *Osteoarth Cartil*. 2013;21(9):1257–63.
10. Snell D, Hipango L, Sinnott J. KA et al. Rehabilitation after total joint replacement: a scoping study. *Disabil Rehabil*. 2018;40(14):1718–31.
11. Tran T, Castello J, Taylor S, et al. Opioid use and appropriateness of supply after total knee of hip arthroplasty: an Australian perspective. *J Am Acad Orthop Surg*. 2020;28(23):e980–e9.
12. Dailiana ZH, Papakostidou I, Varitimidis S, et al. Patient-reported quality of life after primary major joint arthroplasty: a prospective comparison of hip and knee arthroplasty. *BMC Musculoskelet Disord*. 2015;16:366.
13. Dwyer MK, Tumpowsky CM, Hiltz NL, et al. Characterization of Post-Operative Opioid Use Following Total Joint Arthroplasty. *J Arthroplasty*. 2018;33(3):668–72.
14. Tran T, Taylor SE, George J, et al. Evaluation of communication to general practitioners when opioid-naïve post-surgical patients are discharged from hospital on opioids. *ANZ J Surg*. 2020;90(6):1019–24.
15. Rofu A, Boulos D, Hanna M, et al. Validation of a risk stratification tool for a Hospital Outreach Medication Review (HOMR) program. *Res Social Adm Pharm*. 2019;15(9):1133–7.
16. Hanna M, Larmour I, Wilson S, et al. The impact of a hospital outreach medication review service on hospital readmission and emergency department attendances. *J Pharm Pract Res*. 2016;46(2):112–21.
17. Vuong T, Marriott JL, Kong DCM, et al. Implementation of a community liaison pharmacy service: a randomised controlled trial. *Int J Pharm Pract*. 2008;16(3):127–35.
18. Hill MV, McMahan ML, Stucke RS, et al. Wide variation and excessive dosage of opioid prescriptions for common general surgical procedures. *Ann Surg*. 2017;265(4):709–14.
19. Finley EP, Schneegans S, Curtis ME, et al. Confronting challenges to opioid risk mitigation in the U.S. health system: recommendations from a panel of national experts. *PLoS ONE*. 2020;15(6):e0234425.
20. Lemay CA, Lewis CG, Singh JA, et al. Receipt of pain management information preoperatively is associated with improved functional gain after elective total joint arthroplasty. *J Arthroplasty*. 2017;32(6):1763–8.

21. Yajnik M, Hill JN, Hunter OO, et al. Patient education and engagement in postoperative pain management decreases opioid use following knee replacement surgery. *Patient Educ Couns*. 2019;102(2):383–7.
22. Bui T, Grygiel R, Konstantatos A, et al. The impact of an innovative pharmacist-led inpatient opioid de-escalation intervention in post-operative orthopedic patients. *J Opioid Manag*. 2020;16(3):167–76.
23. Genord C, Frost T, Eid D. Opioid exit plan: A pharmacist's role in managing acute postoperative pain. *J Am Pharm Assoc*. 2017;57(2S):S92–8.
24. Klueh MP, Sloss KR, Dossett LA, et al. Postoperative opioid prescribing is not my job: a qualitative analysis of care transitions. *Surgery*. 2019;166(5):744–51.
25. YaDeau JT, Lin Y, Mayman DJ, et al. Pregabalin and pain after total knee arthroplasty: a double-blind, randomized, placebo-controlled, multidose trial. *Br J Anaesth*. 2015;115(2):285–93.

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Springer Nature or its licensor holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.